E21.2
Other hyperparathyroidism
Clinical Classification Guidelines
Inclusion Terms
- Tertiary hyperparathyroidism
Excludes Type 1
- familial hypocalciuric hypercalcemia (E83.52)
Medical Intelligence & Overview
Other hyperparathyroidism, classified under ICD-10 code E21.2, refers to a condition characterized by excessive secretion of parathyroid hormone (PTH) from the parathyroid glands. Unlike primary hyperparathyroidism, which originates due to problems within the glands themselves, or secondary hyperparathyroidism, which results from chronic body conditions like kidney disease, tertiary hyperparathyroidism typically develops in individuals with longstanding secondary hyperparathyroidism. This condition leads to abnormal calcium and phosphorus levels in the body and can have significant impacts on various organ systems, especially the bones and kidneys.
Causes & Symptoms
Clinical Causes: Prolonged secondary hyperparathyroidism, often linked to chronic kidney disease (CKD), especially end-stage renal disease (ESRD). Long-standing disturbances in calcium and phosphorus metabolism prompting parathyroid gland hyperactivity. Parathyroid gland hyperplasia or nodular growth that becomes autonomous over time. Persistent hypocalcemia that causes the parathyroid glands to produce more PTH, eventually leading to tertiary hyperparathyroidism.
Key Symptoms: Bone pain, weakness, or fragility due to increased bone resorption. Elevated blood calcium levels (hypercalcemia), leading to symptoms like nausea, vomiting, constipation, mental confusion, or fatigue. Calcification in soft tissues, including blood vessels and skin. Itching or skin dryness in some cases. Potential cardiovascular issues related to calcium deposits in blood vessels. Symptoms related to underlying kidney disease, such as swelling or changes in urine output.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of blood tests, imaging, and patient history. Key diagnostic steps include: - Blood tests to measure levels of PTH, calcium, phosphorus, and vitamin D. - Assessing kidney function via serum creatinine and estimated glomerular filtration rate (eGFR). - Bone density scans to evaluate bone health. - Imaging studies such as neck ultrasound, sestamib scans, or MRI to examine the parathyroid glands and assess for hyperplasia or adenomas. - Monitoring symptoms and clinical history to confirm the progression from secondary to tertiary hyperparathyroidism.
Treatment Protocols: Managing tertiary hyperparathyroidism involves addressing both the hyperparathyroid state and its underlying causes. Typical approaches include: - Medications such as phosphate binders to control phosphorus levels and vitamin D analogs to suppress PTH secretion. - Calcimimetics (e.g., cinacalcet) to reduce PTH secretion by increasing gland sensitivity to calcium. - Surgical intervention, such as parathyroidectomy (removal of overactive glands), in cases where medication is insufficient or symptoms worsen. - Dialysis optimization, especially for patients with ESRD, to better manage mineral levels. - Monitoring of calcium, phosphorus, and PTH regularly to tailor treatment plans. - Lifestyle modifications including dietary adjustments to regulate phosphate intake.
Clinical Advice & FAQs
Billing Guidance
Is E21.2 a billable ICD-10 code?
Yes, E21.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E21.2?
Clinical documentation must specify the nature of Other hyperparathyroidism and any associated comorbidities for accurate reporting.
Cite this Clinical Reference